<DOC>
	<DOCNO>NCT02377921</DOCNO>
	<brief_summary>UX001-CL301 randomize , double-blind , placebo-controlled study ass safety efficacy 6 g/day sialic acid - extend release ( SA-ER ) treatment compare placebo subject GNE Myopathy .</brief_summary>
	<brief_title>Phase 3 Randomized , Double-Blind , Placebo-Controlled Study Evaluate Sialic Acid Patients With GNE Myopathy ( GNEM ) Hereditary Inclusion Body Myopathy ( HIBM )</brief_title>
	<detailed_description />
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Distal Myopathies</mesh_term>
	<criteria>Male female , age 18 55 year , inclusive Willing able provide write , sign informed consent nature study explain , researchrelated procedure conduct Have document diagnosis GNEM , HIBM , DMRV , Nonaka disease due previously demonstrate mutation gene encode GNE/MNK enzyme ( genotyping conduct study ) Able provide reproducible force elbow flexor ( i.e . two dynamometry force value 15 % variability dominant arm ) Screening Able walk minimum 200 meter 6MWT Screening without use assistive device , include cane , crutch ( e ) , walker , wheelchair scooter ( AFOs permit ) Willing able comply study procedures Participants child‐bearing potential partner childbearing potential undergone bilateral salpingo‐oophorectomy sexually active must consent use highly effective method contraception determine site investigator ( i.e . oral hormonal contraceptive , patch hormonal contraceptive , vaginal ring , intrauterine device , physical doublebarrier method , surgical hysterectomy , vasectomy , tubal ligation , true abstinence [ line prefer usual lifestyle subject ] , mean sex subject chooses ) , period follow signing informed consent 3 month last dose study drug Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include menopause least two year , tubal ligation least one year prior Screening , total hysterectomy bilateral salpingo‐oophorectomy Ingestion NacetylDmannosamine ( ManNAc ) , SA , related metabolite ; intravenous immunoglobulin ( IVIG ) ; anything metabolize produce SA body within 60 day prior Screening Visit History 30 day treatment SAER and/or SAIR prior clinical trial past year Has hypersensitivity SA excipients , judgment investigator , place subject increase risk adverse effect Has serum transaminase ( i.e . aspartate aminotransferase [ AST ] gammaglutamyl transpeptidase [ GGT ] ) level great 3X upper limit normal ( ULN ) age/gender , serum creatinine great 2X ULN Screening Pregnant breastfeed Screening plan become pregnant ( self partner ) time study Use investigational product investigational medical device within 30 day prior Screening , anticipate requirement investigational agent prior completion schedule study assessment Has condition severity acuity , opinion investigator , warrant immediate surgical intervention treatment may allow safe participation study Has concurrent disease , active suicidal ideation , condition , view investigator , place subject high risk poor treatment compliance complete study , would interfere study participation would affect safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>GNE Myopathy</keyword>
	<keyword>GNEM</keyword>
	<keyword>HIBM</keyword>
	<keyword>Nonaka</keyword>
	<keyword>Hereditary Inclusion Body Myopathy</keyword>
	<keyword>DMRV</keyword>
</DOC>